The Morbidity, Recovery and Survivorship Working Committee provides scientific oversight for studies related to preparative regimens, prevention and treatment of early non-Graft-versus-Host Disease toxicities and supportive care in the early post-HCT/cellular therapy period as well as studies regarding issues of long-term survivors of HCT and other cellular therapies, including clinical and psychosocial effects.
Hélène Schoemans
University Hospital Gasthuisberg
Leuven,
Mohamed Sorror
Fred Hutchinson Cancer Center
Seattle, WA
Sairah Ahmed
M.D. Anderson Cancer Center
Houston, TX
Seth Rotz
Cleveland Clinic Foundation
Cleveland, OH
Ruta Brazauskas
CIBMTR - Milwaukee
Milwaukee, WI
Amy Moskop
Rachel Phelan
Andrew Peterson